CELL RECEPTOR DEVELOPS A FUTURE-ORIENTED THERAPY FOR HIGH MEDICAL NEEDS: CANCER AND AUTOIMMUNE DISEASES
Cell Receptor is a small Geneva-based corporation that is building new treatments to prevent metastases in cancer and control autoimmune diseases:
The Cell Receptor team is active in research on cell proliferation regulatory processes and is investigating a very fundamental mechanism of controlling cell division in our body. This has previously not been known and has therefore hardly been the subject of therapeutic efforts. Here, transport mechanisms of signal substances for controlling cell growth are in the foreground.
Cell Receptor also provides insights into pharmacologically useful substances that can inhibit these mechanisms. Based on this, methods were developed for the prevention of cancer metastases and for the suppression of undesired proliferative processes, for example in the immune system. The company owns significant intellectual property for this. Our patents concern the blocking of the transport process by substances that we have found to be effective. We are convinced that the clinical demand will be quite substantial.
Cell Receptor is now planning a clinical trial in collaboration with a renowned hospital as proof of concept. In the sense of repurposing, a substance that we have recognized as effective and that has already been approved will be used.